CD79A and COVID-19: The fact that plasma levels of SARS-CoV-2 RBD IgG/IgA Abs and the frequency of circulating RBD-specific B-cells were similar between controls and HNC is intriguing in the context where cancer patients are considered at high risk for COVID-19 [15,60,61].